- Home
- SBLK vs IMCR Comparison
SBLK vs IMCR Comparison
Compare SBLK & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- IMCR
- Stock Information
- Founded
- SBLK 2006
- IMCR 2008
- Country
- SBLK Greece
- IMCR United Kingdom
- Employees
- SBLK N/A
- IMCR N/A
- Industry
- SBLK Marine Transportation
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBLK Consumer Discretionary
- IMCR Health Care
- Exchange
- SBLK Nasdaq
- IMCR Nasdaq
- Market Cap
- SBLK 2.1B
- IMCR 1.7B
- IPO Year
- SBLK N/A
- IMCR 2021
- Fundamental
- Price
- SBLK $18.57
- IMCR $32.85
- Analyst Decision
- SBLK Buy
- IMCR Buy
- Analyst Count
- SBLK 2
- IMCR 8
- Target Price
- SBLK $21.50
- IMCR $67.86
- AVG Volume (30 Days)
- SBLK 862.9K
- IMCR 327.9K
- Earning Date
- SBLK 11-18-2025
- IMCR 11-06-2025
- Dividend Yield
- SBLK 1.08%
- IMCR N/A
- EPS Growth
- SBLK N/A
- IMCR N/A
- EPS
- SBLK 1.05
- IMCR N/A
- Revenue
- SBLK $1,131,251,000.00
- IMCR $356,145,000.00
- Revenue This Year
- SBLK N/A
- IMCR $29.99
- Revenue Next Year
- SBLK $19.06
- IMCR $8.85
- P/E Ratio
- SBLK $17.64
- IMCR N/A
- Revenue Growth
- SBLK 2.95
- IMCR 26.78
- 52 Week Low
- SBLK $12.06
- IMCR $23.15
- 52 Week High
- SBLK $20.54
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- SBLK 57.18
- IMCR 46.50
- Support Level
- SBLK $17.47
- IMCR $31.36
- Resistance Level
- SBLK $17.98
- IMCR $34.18
- Average True Range (ATR)
- SBLK 0.45
- IMCR 1.45
- MACD
- SBLK 0.13
- IMCR -0.00
- Stochastic Oscillator
- SBLK 88.52
- IMCR 42.17
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.